These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 12402738)

  • 1. Hirudin and its reversal.
    Dornan RI
    Br J Anaesth; 2002 Sep; 89(3):524; author reply 524. PubMed ID: 12402738
    [No Abstract]   [Full Text] [Related]  

  • 2. The direct thrombin inhibitor hirudin.
    Greinacher A; Warkentin TE
    Thromb Haemost; 2008 May; 99(5):819-29. PubMed ID: 18449411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Progress in the controlled release systems of hirudin].
    Li T; Wan C; Li Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 1998 Dec; 15(4):419-23. PubMed ID: 12552793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of ecarin clotting time in whole blood for monitoring recombinant hirudine treatment during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia].
    Devignes J; de Maistre E; Grosjean S; Walter AF; Hacquard M; Mulot A; Longrois D; Carteaux JP; Lecompte T
    Ann Biol Clin (Paris); 2005; 63(2):201-8. PubMed ID: 15771978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of recombinant hirudin: some practical considerations.
    Fareed J; Walenga JM; Hoppensteadt D; Iyer L; Pifarre R
    Semin Thromb Hemost; 1991 Apr; 17(2):137-44. PubMed ID: 1771411
    [No Abstract]   [Full Text] [Related]  

  • 6. Recombinant desulfatohirudin as a substitute for heparin during cardiopulmonary bypass.
    Bernabei A; Rao AK; Niewiarowski S; Colman RW; Sun L; Edmunds LH
    J Thorac Cardiovasc Surg; 1994 Aug; 108(2):381-2. PubMed ID: 8041187
    [No Abstract]   [Full Text] [Related]  

  • 7. [R-hirudin (lepirudin, refludan) as an alternative anticoagulant in heparin-induced thrombocytopenia during cardiopulmonary bypass connection].
    Shah AC; Genoni M; Niederhäuser U; Maloigne M; Turina M
    Schweiz Med Wochenschr; 2000 Jun; 130(23):896-9. PubMed ID: 10897491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic studies with recombinant hirudin in dogs.
    Nowak G; Markwardt F; Fink E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):70-4. PubMed ID: 2459035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hirudins--new antithrombotic agent.
    Katira R; Puri VK
    J Assoc Physicians India; 1994 Mar; 42(3):240-1. PubMed ID: 7860517
    [No Abstract]   [Full Text] [Related]  

  • 10. [A novel high quality specific antithrombotic drug--hirudin].
    Li T; Wan C; Li Y; Chen H
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 1998 Sep; 15(3):306-10. PubMed ID: 12553260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin.
    Fareed J; Walenga JM; Pifarre R; Hoppensteadt D; Koza M
    Haemostasis; 1991; 21 Suppl 1():64-72. PubMed ID: 1894198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-pump coronary artery bypass grafting in a heparin-induced thrombocytopenia type II patient using hirudin.
    Carr CS; Rayner A; Ponte J; Desai JB
    Ann Thorac Surg; 2005 Feb; 79(2):696-8. PubMed ID: 15680867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group.
    Schiele F; Lindgaerde F; Eriksson H; Bassand JP; Wallmark A; Hansson PO; Grollier G; Sjo M; Moia M; Camez A; Smyth V; Walker M
    Thromb Haemost; 1997 May; 77(5):834-8. PubMed ID: 9184388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time.
    Pötzsch B; Madlener K; Seelig C; Riess CF; Greinacher A; Müller-Berghaus G
    Thromb Haemost; 1997 May; 77(5):920-5. PubMed ID: 9184403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of bivalirudin anticoagulation during and after cardiopulmonary bypass using an ecarin-activated TEG system.
    Koster A; Buz S; Krabatsch T; Dehmel F; Hetzer R; Kuppe H; Dyke C
    J Card Surg; 2008; 23(4):321-3. PubMed ID: 18482390
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of recombinant hirudins in the management of thrombotic disorders.
    Fischer KG
    BioDrugs; 2004; 18(4):235-68. PubMed ID: 15244501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of different hirudins and combinations of low doses of hirudin, heparin and acetylsalicylic acid in a rat microcirculatory thrombosis model.
    Krupinski K; Breddin HK
    Haemostasis; 1991; 21 Suppl 1():88-92. PubMed ID: 1894199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged bleeding after cardiopulmonary bypass with recombinant hirudin in heart transplantation.
    Kwapisz MM; Schindler E; Müller M; Akintürk H
    Eur J Cardiothorac Surg; 1999 Aug; 16(2):256-7. PubMed ID: 10485435
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacology of recombinant hirudin.
    Nowak G
    Semin Thromb Hemost; 2002 Oct; 28(5):415-24. PubMed ID: 12420236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
    Cofrancesco E; Cortellaro M; Leonardi P; Corradi A; Ravasi F; Bertocchi F
    Thromb Haemost; 1996 Mar; 75(3):407-11. PubMed ID: 8701398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.